Nuvation Bio Inc.
NUVB- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001811063
In the last 90 days, Nuvation Bio Inc. insiders filed 0 open-market purchases and 1 sale; 244 institutions reported holding it in 13F filings for Q2 2026, worth $1.33B in total; 3 superinvestors hold it, including Duquesne Family Office and Abrams Capital.
Superinvestors holding NUVB, Q2 2026
3 superinvestors report holding Nuvation Bio Inc. on Form 13F, worth $33.2M in total. Weight is Nuvation Bio Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Duquesne Family OfficeStanley Druckenmiller | 0.6% | 4,539,800 | $25.8M | Unchanged |
| Abrams CapitalDavid Abrams | 0.1% | 1,270,504 | $7.22M | Unchanged |
| Greenlight CapitalDavid Einhorn | <0.1% | 34,995 | $198.8K | Unchanged |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of NUVB each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q1 2026
3 superinvestors holding at quarter end
- New
- Duquesne Family Office
- Reduced
- Abrams Capital (−66.7%)
Q1 2023
2 superinvestors holding at quarter end
- Sold out
- Baupost Group
Q4 2022
3 superinvestors holding at quarter end
- Reduced
- Baupost Group (−53.8%)
Q2 2022
3 superinvestors holding at quarter end
- Reduced
- Baupost Group (−0.2%)
Q1 2022
3 superinvestors holding at quarter end
- Added
- Baupost Group (+21.1%)
Q2 2021
3 superinvestors holding at quarter end
- Reduced
- Greenlight Capital (−76.7%)